Advanced Science, EarlyView.Particulate matter ≤2.5 µm (PM2.5) elevates risks of neurological and chronic metabolic diseases, but the underlying mechanisms linking PM2.5‐induced central nervous system (CNS) injury to metabolic dysfunction remain unclear. Hypothalamic pro‐opiomelanocortin‐expressing (POMC+) neurons regulate systemic metabolic homeostasis, and tripartite motif ...
Chenxu Ge +21 more
wiley +1 more source
Hepatic macrophages in liver fibrosis: pathogenesis and potential therapeutic targets
BMJ Open Gastroenterology, 2016 Hepatic macrophages account for the largest non-parenchymal cell population in the liver. Recent studies have found that hepatic macrophages have different functions in different stages of experimental liver fibrosis.
Hai Li, Hong You, Jidong Jia, Xu Fan
doaj +1 more source
Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets [PDF]
, 2013 Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in children. NAFLD has emerged to be extremely prevalent, and predicted by obesity and male gender.
Giorgio V +3 more
core +1 more source
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, 2019 Background Nonalcoholic fatty liver disease (NAFLD) is a multifactorial disorder that can progress to fibrosis. Several dietary patterns have been associated with histological features of NAFLD.
Davood Soleimani +5 more
semanticscholar +1 more source
Decoding Human Placental Cellular and Molecular Responses to Obesity and Fetal Growth
Advanced Science, EarlyView.Women with obesity often deliver large‐for‐gestational‐age (LGA) infants. Single‐nucleus RNA sequencing of term placenta reveals that hypoxia and TNF‐α signaling in syncytiotrophoblasts are featured in maternal obesity, but inflammatory signatures in Hofbauer cells and response to lipid or carbohydrate metabolism in fibroblasts are specific to LGA.
Hong Jiang +12 more
wiley +1 more source
Combination Therapy with Vitamin D and Telmisartan to Suppress the Progression of Liver Fibrosis. [PDF]
Journal of Medical and Life ScienceHepatic fibrosis is an improper wound repair response associated with various kinds of chronic liver injuries. It can be detected by over-deposition of diffuse ECM (Extracellular Matrix) and abnormal overgrowth of connective tissue, and it can progress ...
Fatma Amer +2 more
doaj +1 more source
Anticoagulant therapy with fondaparinux in a liver transplant patient with thrombosis and liver fibrosis: a case report [PDF]
, 2017 The treatment with fondaparinux is the effective and safe anticoagulant therapy in liver transplant patient on immunosuppressive therapy with arterial thrombosis, and it seems able to reduce liver fibrosis.
Cafolla, Arturo, Gentile, Giuseppe
core +1 more source
Metabolic Signature of Hepatic Fibrosis: From Individual Pathways to Systems Biology
Cells, 2019 Hepatic fibrosis is a major cause of morbidity and mortality worldwide, as it ultimately leads to cirrhosis, which is estimated to affect up to 2% of the global population.
Ming-Ling Chang, Sien‐Sing Yang
semanticscholar +1 more source
Lactylation‐Driven YTHDC1 Alleviates MASLD by Suppressing PTPN22‐Mediated Dephosphorylation of NLRP3
Advanced Science, EarlyView.In MASLD, YTHDC1 undergoes increased lactylation and ubiquitination, reducing its expression. AARS1 mediates lactylation at lysine 565, while disrupted binding to LDHA further promotes lactylation, suppressing YTHDC1. This downregulation enhances PTPN22 mRNA stability, leading to NLRP3 dephosphorylation and activation, which exacerbates inflammation ...
Feng Zhang +16 more
wiley +1 more source
Congenital hepatic fibrosis [PDF]
Postgraduate Medical Journal, 1967 A R, Lorimer, J, McGee, S G, McAlpine
openaire +4 more sources